Reshma Kewalramani, Vertex CEO (Barry Chin/The Boston Globe via Getty Images)
Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease
Reshma Kewalramani is putting Vertex’s $10 billion-plus balance sheet to work.
On Wednesday, the biotech announced it would pay $4.9 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
